DMK Pharmaceuticals (0A4X) Stock Statistics & Valuation Metrics

DMK Pharmaceuticals has a market cap or net worth of $10.00. The enterprise value is ―.

DMK Pharmaceuticals has 10,102,050 shares outstanding. The number of shares has decreased by -2.65% in one year.

DMK Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of DMK Pharmaceuticals is ―. DMK Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, DMK Pharmaceuticals had revenue of 4.76M and earned -26.48M in profits. Earnings per share was -12.37.

In the last 12 months, operating cash flow was -9.38M and capital expenditures -91.49K, giving a free cash flow of -9.47M billion.

DMK Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

DMK Pharmaceuticals upcoming earnings date is Nov 12, 2024, TBA Not Confirmed.

DMK Pharmaceuticals as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, DMK Pharmaceuticals has paid 2.00K in taxes.

DMK Pharmaceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

DMK Pharmaceuticals has $6.66M in cash and marketable securities with $63.21K in debt, giving a net cash position of -$6.60M billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for DMK Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―